SecSonar.com

Aligos Therapeutics, Inc. (ALGS)

Aligos Therapeutics, Inc. at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.

Aligos Therapeutics, Inc. (ALGS) is a Biotechnology company based in US with a market capitalization of $35.5M. Revenue declined 44.6% year-over-year and free cash flow was negative at -$82.9M. This page tracks ALGS's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.

US · 70 employees · IPO Oct 16, 2020

Valuation

Valuation & price

$5.71 · as of May 17, 2026 · -57.1% vs 52w high

—

P/E ratio

Latest-FY diluted EPS

0.66

P/B ratio

Market cap ÷ book equity

—

Dividend yield

Price — last 12 months

$13.30$9.11$4.91Jul 25Dec 25Jul 26Jul 7, 25$7.50Jul 9, 25$8.66Jul 11, 25$8.36Jul 15, 25$8.50Jul 17, 25$9.04Jul 21, 25$8.64Jul 23, 25$9.28Jul 25, 25$9.13Jul 29, 25$8.04Jul 31, 25$7.28Aug 4, 25$8.00Aug 6, 25$8.04Aug 11, 25$7.57Aug 13, 25$7.65Aug 15, 25$7.70Aug 19, 25$8.82Aug 21, 25$9.84Aug 25, 25$10.21Aug 27, 25$11.33Aug 29, 25$10.55Sep 3, 25$10.80Sep 5, 25$11.34Sep 9, 25$11.22Sep 11, 25$10.88Sep 16, 25$8.95Sep 18, 25$9.99Sep 22, 25$9.53Sep 24, 25$10.75Sep 26, 25$9.79Sep 30, 25$9.80Oct 2, 25$10.24Oct 6, 25$10.22Oct 8, 25$9.93Oct 10, 25$9.43Oct 14, 25$9.66Oct 16, 25$10.51Oct 21, 25$10.49Oct 23, 25$9.49Oct 27, 25$9.77Oct 29, 25$8.61Oct 31, 25$8.25Nov 4, 25$7.21Nov 6, 25$7.10Nov 10, 25$6.89Nov 12, 25$6.46Nov 14, 25$6.66Nov 18, 25$7.92Nov 20, 25$8.26Nov 25, 25$9.66Nov 28, 25$9.58Dec 2, 25$9.21Dec 4, 25$10.09Dec 8, 25$10.78Dec 10, 25$11.33Dec 12, 25$13.30Dec 16, 25$11.47Dec 18, 25$10.37Dec 22, 25$10.75Dec 24, 25$10.52Dec 29, 25$9.65Jan 2, 26$9.13Jan 6, 26$8.76Jan 8, 26$10.33Jan 12, 26$8.71Jan 14, 26$9.05Jan 16, 26$7.94Jan 21, 26$8.00Jan 23, 26$8.12Jan 27, 26$8.59Jan 29, 26$8.12Feb 2, 26$7.95Feb 4, 26$7.07Feb 9, 26$7.23Feb 11, 26$7.46Feb 13, 26$6.91Feb 18, 26$6.80Feb 20, 26$6.80Feb 24, 26$7.09Feb 26, 26$7.50Mar 2, 26$6.97Mar 4, 26$6.86Mar 6, 26$6.98Mar 10, 26$7.10Mar 12, 26$7.41Mar 17, 26$7.30Mar 19, 26$7.34Mar 23, 26$6.87Mar 25, 26$6.96Mar 27, 26$6.66Mar 31, 26$7.43Apr 2, 26$7.97Apr 7, 26$7.90Apr 9, 26$7.94Apr 13, 26$8.64Apr 15, 26$7.42Apr 17, 26$6.68Apr 22, 26$6.51Apr 24, 26$6.40Apr 28, 26$6.29Apr 30, 26$5.99May 4, 26$6.44May 6, 26$6.37May 8, 26$6.44May 12, 26$6.47May 14, 26$6.69May 18, 26$5.36May 20, 26$5.60May 22, 26$5.76May 28, 26$5.79Jun 1, 26$5.35Jun 3, 26$5.14Jun 5, 26$4.91Jun 9, 26$5.14Jun 11, 26$5.28Jun 15, 26$5.11Jun 17, 26$5.35Jun 22, 26$5.69Jun 24, 26$5.58Jun 26, 26$5.57Jul 2, 26$5.59
$4.9152-week range$13.30
Loading valuation history…

Fundamentals

Key fundamentals

$35.5M

Market cap

-44.6%

Revenue growth (YoY)

57.5%

Gross margin

-$82.9M

Free cash flow (USD)

-$72.6M

Net debt

Net cash position

57.8%

Share dilution

2/5

Graham criteria passed

Defensive-investor screen

Healthcare

Sector

Trajectory

Long-term trends

Revenue by year

2018 → 2025

FY 2018$0.00FY 2019$0.00FY 2020$0.00FY 2021$4.4MFY 2022$13.9MFY 2023$15.5MFY 2024$3.9MFY 2025$2.2M
$0$2.2M

Free cash flow by year

2018 → 2025

FY 2018$-8.6MFY 2019$-49.6MFY 2020$-76.3MFY 2021$-116.6MFY 2022$-80.3MFY 2023$-79.0MFY 2024$-80.9MFY 2025$-82.9M
-$8.6M-$82.9M

Gross margin by year

2021 → 2025

FY 2021100.0%FY 2022100.0%FY 2023100.0%FY 2024100.0%FY 202557.5%
100.0%57.5%

Value screen

Graham defensive-investor tests

Computing the scorecard — refreshing any stale inputs…

0

Insider buys · 90 days

0

Insider sells · 90 days

Earnings

Last report: 10-Q filed May 7, 2026

Next expected: not yet scheduled

On the tape

Recent SEC & insider activity

  • 8-K eventEmployee Stock Purchase Plan AmendmentJun 26, 2026Filing
  • 8-K eventEarnings ReleaseMay 7, 2026Filing
  • Quarterly report10-Q FiledMay 7, 2026Filing
  • 8-K eventLicense Agreement SignedApr 21, 2026Filing
  • 8-K eventInterim Study ResultsApr 14, 2026Filing

Questions

Frequently asked questions

What is Aligos Therapeutics, Inc.'s market cap?

Aligos Therapeutics, Inc. (ALGS) has a market capitalization of $35.5M.

What is ALGS's P/E ratio?

A meaningful P/E ratio is not available for ALGS — the company's latest fiscal-year earnings per share is zero, negative, or not yet cached.

What is ALGS's price-to-book (P/B) ratio?

ALGS trades at 0.66 times book value per share.

Are insiders buying ALGS stock?

SEC Form 4 filings show no open-market insider buys at Aligos Therapeutics, Inc. in the last 90 days (0 sells).

Same arena

Related companies in Biotechnology

RNXT

RenovoRx, Inc.

$35M

INMB

INmune Bio, Inc.

$36.3M

SABS

SAB Biotherapeutics, Inc.

$34.6M

ATHE

Alterity Therapeutics Limited

$36.5M

BTAI

BioXcel Therapeutics, Inc.

$37.1M

VERU

Veru Inc.

$37.4M

Timeline

Every filing, insider trade & earnings on a price-anchored timeline

Filing Analyzer

Search the actual 10-K / 10-Q text with AI research angles

News

Latest press coverage in one feed

Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.